Profile image
By marketresearchnest
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Hepatitis D Therapeutics Market Pipeline Review H1 2017

Friday, May 19, 2017 5:38
% of readers think this story is Fact. Add your two cents.

(Before It's News) adds “Hepatitis D – Pipeline Review, H1 2017” new report to its research database. The report spread across in multiple pages with table and figures in it.


Latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D – Pipeline Review, H1 2017, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Browse full table of contents and data tables at

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


Hepatitis D – Companies Involved in Therapeutics Development

“Alnylam Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Spring Bank Pharmaceuticals Inc”


Order a Purchase Report Copy at


Featured News & Press Releases
May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling
Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017
Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
Apr 04, 2017: Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Feb 20, 2017: Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017
Nov 15, 2016: Replicor Discloses Late Breaking HBV and Follow-Up HBV / HDV Clinical Data at AASLD 2016
Nov 14, 2016: Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting
Oct 19, 2016: Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus Infection
Oct 13, 2016: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting
Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School
Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health
Jun 01, 2016: Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
May 25, 2016: Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection
Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B
Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016


Scope of this Report

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)


Request Sample Copy at


About Us:                  is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.


Contact Us

Mr. Jeet Jain

Sales Manager


Connect with us:  Google+ | LinkedIn | Twitter | Facebook

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.